IL-25/IL-33–responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa

Emily P. S. Lam, PhD,1,8 Harsha H. Kariyawasam, FRCP, PhD,2,8 Batika M. J. Rana, PhD,3,8 Stephen R. Durham, MD, FRCP,4,8 Andrew N. J. McKenzie, PhD,3 Nicholas Powell, MRCP, PhD,5 Nara Orban, MD,4 Melissa Lennartz-Walker, MSc,1,8 Claire Hopkins, FRCS (ORL-HNS),7 Sun Ying, MD, PhD,1 Joanne Rimmer, FRCS (ORL-HNS),2 Valerie J. Lund, MD, FRCS,2 David J. Cousins, PhD,5,8 and Stephen J. Till, FRCP, PhD1,8 1The Division of Asthma, Allergy and Lung Biology, Guy’s Hospital, King’s College London; 2the Allergy and Medical Rhinology Section, Royal National Throat Nose Ear Hospital, University College London; 3the Medical Research Council Laboratory of Molecular Biology, Cambridge; 4the Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London; 5the Division of Transplantation Immunology and Mucosal Biology and Medical Research Council Centre for Transplantation, King’s College London; 6the Department of Infection, Immunity and Inflammation, NIHR Leicester Respiratory Biomedical Research Unit, Leicester Institute for Lung Health, University of Leicester; 7the Department of ENT, Guy’s and St Thomas’ Hospital, London; and 8the Medical Research Council and Asthma UK Centre in Allergic Mechanisms of Asthma, London.